SCHEMBL20147542

SCHEMBL20147542

CC(C)N1CCC(NC(=O)c2cccc(F)c2F)C1

nearest known ligand 0.51

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 9/20 0.51
HTR1A P08908 1/20 0.51
DRD2 P14416 1/20 0.51
HTR7 P34969 1/20 0.51
HTR6 P50406 1/20 0.51
WNT1 P04628 1/20 0.49
DYRK1A Q13627 1/20 0.49
KDM5A P29375 1/20 0.47
USP30 Q70CQ3 2/20 0.45
PARP1 P09874 1/20 0.45
KDM4D Q6B0I6 1/20 0.45
SLC6A5 Q9Y345 1/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20147541 0.86 L3MBTL1 (0.54) HRH3WNT1DYRK1AKDM5ASLC6A5
SCHEMBL20205999 0.81 HTR7 (0.61) HTR1ADRD2HTR7HTR6MEN1
SCHEMBL21779907 0.79 GAA (0.50) HRH3KDM5AKDM4DMEN1KMT2A
SCHEMBL3170903 0.78 P2RX7 (0.57) HTR1ADRD2HTR7HTR6
SCHEMBL10168794 0.77 HRH3 (0.67) HRH3KDM5ASLC6A5MEN1KMT2A
SCHEMBL20147538 0.77 HRH3 (0.67) HRH3KDM5ASLC6A5MEN1KMT2A
SCHEMBL22643851 0.77 HRH3 (0.67) HRH3KDM5ASLC6A5MEN1KMT2A
SCHEMBL13162922 0.73 NPC1 (0.65) MEN1KMT2A
SCHEMBL31188489 0.73 NPC1 (0.56) HTR1ADRD2HTR7HTR6KDM5A
SCHEMBL10168782 0.73 HRH3 (0.70) HRH3SLC6A5KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11648243-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2023-05-16 US disclosed
US-10881652-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2021-01-05 US disclosed
US-10172845-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2019-01-08 US disclosed
US-20180148445-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-31 US disclosed
US-20180134703-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 US disclosed
US-20180133207-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 US disclosed
US-20180134703-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10881652-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, BRAF, RAF1 HRH3 1000/4885HTR1A 3345/4885DRD2 3425/4885
US-20180148445-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 HRH3 1000/4885HTR1A 3345/4885DRD2 3425/4885
US-11648243-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, BRAF, RAF1 HRH3 1000/4885HTR1A 3345/4885DRD2 3425/4885
US-10172845-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, BRAF, RAF1 HRH3 1000/4885HTR1A 3345/4885DRD2 3425/4885
US-20180133207-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 HRH3 1000/4885HTR1A 3345/4885DRD2 3425/4885
US-20180134703-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 HRH3 1000/4885HTR1A 3345/4885DRD2 3425/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.